1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Cumulative Impact of COVID-19

6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology

7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon

8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing

9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL BIOSIMILARS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILARS MARKET: MARKET DYNAMICS
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2027 (%)
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2027
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2027 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2027 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2027 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2027 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2027 (%)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2027 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2027
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2027 (USD MILLION)
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2027 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2027 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2027 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2027 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2027 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2027 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2027 (USD MILLION)
FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2027 (USD MILLION)
FIGURE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2027 (USD MILLION)
FIGURE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2027 (USD MILLION)
FIGURE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2027 (USD MILLION)
FIGURE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2027 (USD MILLION)
FIGURE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2027 (%)
FIGURE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2027 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2027
FIGURE 58. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2027 (USD MILLION)
FIGURE 59. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2027 (USD MILLION)
FIGURE 61. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 62. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. CANADA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. MEXICO BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. CHINA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. INDIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 73. JAPAN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 75. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. THAILAND BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. FRANCE BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. GERMANY BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. ITALY BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 85. QATAR BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 86. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 87. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 88. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 89. SPAIN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 90. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 91. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 92. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX
FIGURE 93. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 94. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILARS MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL BIOSIMILARS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2027 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2027 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2027 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2027 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2027 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2027 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2027 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2027 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2027 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2027 (USD MILLION)
TABLE 31. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 32. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 34. CANADA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. MEXICO BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 38. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. CHINA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 40. INDIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 41. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 42. JAPAN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 44. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 45. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 46. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 47. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 48. THAILAND BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 50. FRANCE BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 51. GERMANY BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 52. ITALY BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 53. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 54. QATAR BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 55. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 56. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 57. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 58. SPAIN BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 59. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 60. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 62. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 63. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 64. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 65. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 66. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 67. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 68. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 69. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 70. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 71. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING

Companies Mentioned

AMEGA Biotech S.A.
Amgen Inc.
Apotex Inc.
Biosidus S.A.
Bioton S.A.
Innovent Biologics, Inc.
JHL Biotech, Inc.
LG Chem, Ltd.
Merck Sharp & Dohme Corp.
Mylan N.V.
Pfizer Inc.
Sandoz International GmbH